What does high-risk means in a patient who is diagnosed with multiple myeloma? What are the markers that determine the most common sub-category of high-risk myeloma? What are the best treatments for high-risk disease and what are the most promising related current clinical trials?
Listen in to get answers to these and more questions from Dr.
Rafael Fonseca deputy director, Mayo Clinic Cancer Center.
